Latest filing published 28 Oct 2026 for Lycia Therapeutics, Inc..
Insider track record
No signal scores available.
Versant Ventures VII GP, L.P.: trading record in brief
Versant Ventures VII GP, L.P. is a declared insider of Lycia Therapeutics, Inc., with filings sourced from SEC (Form 4). In total, 2 filings cover trades dated 26 October 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
On 28 October 2026 came the latest disclosure, a transaction in Lycia Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Versant Ventures VII GP, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,631,425 sharesCommon StockSEC:0001193125-26-436415:0
- 1,393,882 sharesCommon StockSEC:0001193125-26-436415:1
2 of 2 declarations
